Atreca to Present at Upcoming Investor Conferences

SAN CARLOS, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming investor conferences:

H.C. Wainwright Global Investment Conference
May 23-26, 2022
Presentation: 8:30 am EDT, May 25, 2022

Cowen’s 3rd Annual Oncology IO Next Summit
June 2, 2022
Presentation: 2:00 pm EDT, June 2, 2022

Jefferies Healthcare Conference
June 8-10, 2022
Fireside Chat: 9:00 am EDT, June 9, 2022

A live audio webcast of each presentation can be accessed through the Events & Presentations section of the Company's website at http://ir.atreca.com. An archived replay will be available on the Company's website for 30 days following each event.

About Atreca, Inc.
Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101, a monoclonal antibody targeting a novel RNP complex, and ATRC-301, an ADC targeting a novel epitope on EphA2. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients, and ATRC-301 is in IND-enabling studies. For more information on Atreca, please visit www.atreca.com.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding our strategy and future plans, including statements regarding the development of ATRC-101, ATRC-301, and our preclinical and clinical plans and the timing thereof. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

Contacts

Atreca, Inc.
Herb Cross
Chief Financial Officer
[email protected]

Investors:
Alex Gray, 650-779-9251
[email protected]

Media:
Julia Fuller, 858-692-2001
[email protected]

Source: Atreca, Inc.

You May Also Be Interested In

• Definium Therapeutics prices $700M public offering at $34 per share
• MSCI acquires First Street for $120M to expand climate risk data
• Smart Digital Group faces Nasdaq delisting after SEC trading suspension